Forte Biosciences (FBRX) Consolidated Net Income (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Consolidated Net Income of -$22.1 million for Q1 2026, down 41.39% year-over-year from -$37.8 million in Q1 2025, and up 10.07% quarter-over-quarter from -$24.6 million in Q4 2025.
Forte Biosciences (FBRX) Consolidated Net Income (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Consolidated Net Income for 11 consecutive years, with -$22.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 41.39% year-over-year to -$22.1 million; the TTM figure through Mar 2026 stood at -$107.2 million (down 140.3% YoY), while the FY2025 annual figure was -$73.5 million, down 2655.51% from the prior year.
- Consolidated Net Income grew to -$22.1 million in Q1 2026 per FBRX's latest filing, from -$24.6 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$2.8 million in Q1 2022 and bottomed at -$35.8 million in Q3 2025.
- Historically, Consolidated Net Income has averaged -$12.2 million across 5 years, with a median of -$8.7 million in 2024.
- Annual changes were most pronounced in 2022 — Consolidated Net Income soared 90.32% — and 2025, when it plunged 313.47%.
- Forte Biosciences' Consolidated Net Income stood at -$5.0 million in 2022, then decreased by 28.12% to -$6.4 million in 2023, then slipped by 15.93% to -$7.4 million in 2024, then slumped by 231.19% to -$24.6 million in 2025, then climbed by 10.07% to -$22.1 million in 2026.
- Business Quant data shows FBRX's Consolidated Net Income at -$22.1 million in Q1 2026, -$24.6 million in Q4 2025, and -$35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -23.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.33 Mn |
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | -24.61 Mn |
| Sep 30, 2025 | -35.79 Mn |
| Jun 30, 2025 | -24.61 Mn |
| Mar 31, 2025 | -15.66 Mn |
| Dec 31, 2024 | -7.43 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Jun 30, 2024 | -12.85 Mn |
| Mar 31, 2024 | -7.83 Mn |
| Dec 31, 2023 | -6.41 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.12 Mn |
| Mar 31, 2023 | -6.93 Mn |
| Dec 31, 2022 | -5.00 Mn |
| Sep 30, 2022 | -3.52 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -2.82 Mn |
| Dec 31, 2021 | -3.92 Mn |
| Sep 30, 2021 | -8.74 Mn |